Survival rates and treatments costs for pleural mesothelioma patients prior to the emergence of immunotherapy
Pleural mesothelioma is an aggressive cancer that develops on the mesothelial lining of the lung which serves to lubricate and facilitate movement of the lung within the chest cavity. Mesothelioma is caused by exposure to asbestos and can take decades… Read More »
Read MoreImmunotherapy for mesothelioma shows durable benefits
Key Findings At five years, 14 percent of patients treated with the immunotherapy combination were still alive, compared with 6 percent of those who received chemotherapy. In patients with epithelioid mesothelioma, the five-year overall survival rate was 14 percent with… Read More »
Read MoreA study into the experience of caregivers yields first findings
A study examining the experience of caregivers of mesothelioma patients is currently underway, and results from its first phase have been released. The study Understanding the Mesothelioma Journey from Diagnosis through Bereavement, Innovation in Aging, Volume 9, Issue Supplement_2 was published… Read More »
Read MoreWhat the 2025 iMig Conference Revealed About the Future of Mesothelioma Treatment
The biannual meeting of the International Mesothelioma Interest Group (iMig) brought forward a mix of clinical insights, scientific advances, and ongoing debates that continue to shape the care of patients with mesothelioma. Several themes rose to the forefront, from how… Read More »
Read MoreCOVID-19 mRNA vaccine makes tumors respond better to immunotherapy
Recently, oncology researchers were energized by new findings published in Nature, showing that immune therapies such as nivolumab (Opdivo) and ipilimumab (Yervoy) may work better when given alongside an mRNA-based COVID-19 vaccine. These drugs are known as immune checkpoint inhibitors,… Read More »
Read MoreExperts, Patients, and Advocates Unite in Philadelphia to Advance Mesothelioma Research
The Mesothelioma Applied Research Foundation hosted its annual International Symposium on Malignant Mesothelioma in Philadelphia, drawing together a vibrant mix of scientists, physicians, patients, and advocates. Over the course of two days, participants shared the latest discoveries in treatment and… Read More »
Read MoreNavigating a Mesothelioma Diagnosis: Interview with Thoracic Surgeon Dr. Christopher Towe
Mesothelioma is one of the most aggressive and devastating forms of cancer. This rare cancer, which is caused by asbestos exposure, is difficult to diagnose, and even more challenging to treat, making it critically important for patients to seek care… Read More »
Read MoreCannabis and mesothelioma: can cannabis help with disease and treatment side-effects?
Last week, during the International Symposium on Malignant Mesothelioma, Dr. Carol Parise presented on the topic of cannabis and mesothelioma. This is a topic of interest to many because while cannabis is already in use by many cancer patients outside… Read More »
Read MoreBelluck Law Sponsors Mesothelioma Patient Conference in October
The law firm of Belluck Law is a top sponsor of the Mesothelioma Applied Research Foundation’s annual conference which will take place on October 17-18, 2024, in Chicago. The firm’s partner, Joe Belluck, Esq., will be a speaker on the… Read More »
Read MoreFirst ever FDA-approval of immunotherapy plus chemotherapy combination for advanced mesothelioma
Today, the U.S. Food and Drug Administration (FDA) approved the third ever treatment for mesothelioma. As of today, in addition to the standard chemotherapy regimen and the immunotherapy regimen, the combination of immunotherapy plus standard chemotherapy is available to clinicians… Read More »
Read More